NYSE - Delayed Quote USD

Johnson & Johnson (JNJ)

151.22 +1.31 (+0.87%)
At close: May 13 at 4:00 PM EDT
151.35 +0.13 (+0.09%)
Pre-Market: 7:09 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
85,648,000.00
85,159,000.00
79,990,000.00
78,740,000.00
82,584,000.00
Cost of Revenue
26,377,000.00
26,553,000.00
24,596,000.00
23,402,000.00
28,427,000.00
Gross Profit
59,271,000.00
58,606,000.00
55,394,000.00
55,338,000.00
54,157,000.00
Operating Expense
35,835,000.00
35,197,000.00
33,181,000.00
34,395,000.00
34,424,000.00
Operating Income
23,436,000.00
23,409,000.00
22,213,000.00
20,943,000.00
19,733,000.00
Net Non Operating Interest Income Expense
712,000.00
489,000.00
214,000.00
-130,000.00
-90,000.00
Other Income Expense
-4,087,000.00
-8,802,000.00
-3,058,000.00
-1,635,000.00
-3,146,000.00
Pretax Income
20,063,000.00
15,062,000.00
19,359,000.00
19,178,000.00
16,497,000.00
Tax Provision
2,991,000.00
1,736,000.00
2,989,000.00
1,377,000.00
1,783,000.00
Net Income Common Stockholders
38,476,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Diluted NI Available to Com Stockholders
38,476,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Basic EPS
15.26
13.88
6.86
7.93
5.59
Diluted EPS
15.09
13.72
6.73
7.81
5.51
Basic Average Shares
2,484,175.00
2,533,500.00
2,613,597.00
2,628,965.00
2,632,512.00
Diluted Average Shares
2,516,550.00
2,560,400.00
2,663,900.00
2,674,000.00
2,670,700.00
Total Expenses
62,212,000.00
61,750,000.00
57,777,000.00
57,797,000.00
62,851,000.00
Net Income from Continuing & Discontinued Operation
38,476,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Normalized Income
20,975,168.22
21,292,770.00
19,380,068.00
18,830,152.00
14,934,324.00
Interest Income
1,427,000.00
1,261,000.00
490,000.00
53,000.00
111,000.00
Interest Expense
715,000.00
772,000.00
276,000.00
183,000.00
201,000.00
Net Interest Income
712,000.00
489,000.00
214,000.00
-130,000.00
-90,000.00
EBIT
20,778,000.00
15,834,000.00
19,635,000.00
19,361,000.00
16,698,000.00
EBITDA
28,199,000.00
23,320,000.00
26,605,000.00
26,751,000.00
23,929,000.00
Reconciled Cost of Revenue
26,377,000.00
26,553,000.00
24,596,000.00
23,402,000.00
28,427,000.00
Reconciled Depreciation
7,421,000.00
7,486,000.00
6,970,000.00
7,390,000.00
7,231,000.00
Net Income from Continuing Operation Net Minority Interest
17,072,000.00
13,326,000.00
16,370,000.00
17,801,000.00
14,714,000.00
Total Unusual Items Excluding Goodwill
-4,587,000.00
-9,002,000.00
-3,558,000.00
-1,109,000.00
-247,000.00
Total Unusual Items
-4,587,000.00
-9,002,000.00
-3,558,000.00
-1,109,000.00
-247,000.00
Normalized EBITDA
32,786,000.00
32,322,000.00
30,163,000.00
27,860,000.00
24,176,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-683,831.78
-1,035,230.00
-547,932.00
-79,848.00
-26,676.00
12/31/2020 - 1/2/1962

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE Pfizer Inc.
28.44
+1.54%
 
ABBV AbbVie Inc.
161.28
+0.33%
 
MRK Merck & Co., Inc.
129.29
-0.59%
 
BMY Bristol-Myers Squibb Company
45.06
+0.27%
 
LLY Eli Lilly and Company
757.70
-0.30%
 
AMGN Amgen Inc.
308.45
-0.55%
 
GILD Gilead Sciences, Inc.
67.54
+2.40%
 
AZN AstraZeneca PLC
77.43
+0.32%
 
GSK GSK plc
45.17
+0.22%
 
SNY Sanofi
50.21
+1.89%